ROR1 antibody-modified lipid nanoparticles, their preparation methods, and applications.

By preparing lipid nanoparticles modified with monoclonal antibodies against ROR1, the problems of unstable antibody conjugation efficiency and insufficient binding affinity in existing systems were solved, achieving efficient targeted delivery of TNBC and significant anti-tumor effects.

CN123106901APending Publication Date: 2026-11-17UNIV OF MACAU
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611051849.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-07-15
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing ROR1-targeted lipid nanoparticle delivery systems for TNBC treatment suffer from problems such as unstable antibody conjugation efficiency, poor particle size uniformity, and insufficient binding affinity, failing to meet the requirements of high targeting specificity and low off-target toxicity. Furthermore, research on TNBC is relatively limited.

Method used

Develop a monoclonal antibody against ROR1 or its antigen-binding fragment, and combine it with a lipid nanoparticle preparation method to prepare ROR1 antibody-modified lipid nanoparticles Lip(MMAE)-Hu3 by thin-film hydration. The inner layer encapsulates the cytotoxin MMAE, and the outer layer is modified with Hu3-H10-F4 IgG antibody for targeting triple-negative breast cancer cells.

Benefits of technology

It significantly improved the targeting effect on triple-negative breast cancer cells, significantly inhibited intracellular microtubule protein expression, and demonstrated significant anti-tumor effects in xenograft mouse models.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

This invention belongs to the field of biomedical technology and discloses ROR1 antibody-modified lipid nanoparticles, their preparation methods, and applications. This invention provides an anti-ROR1 monoclonal antibody or its antigen-binding fragment. The monoclonal antibody or its antigen-binding fragment includes a murine anti-ROR1 monoclonal antibody and a single-chain antibody, and a humanized anti-ROR1 monoclonal antibody and a single-chain antibody. The murine anti-ROR1 monoclonal antibody is obtained using hybridoma technology, and the heavy chain variable region and light chain variable region of the humanized antibody are derived from the murine anti-ROR1 monoclonal antibody. The humanized variable region sequence is constructed onto a human IgG1 antibody backbone to obtain a humanized anti-ROR1 monoclonal antibody (Hu 3-H10-F4 IgG). The above antibody exhibits good affinity and endocytic ability.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of biomedical technology, specifically relating to ROR1 antibody-modified lipid nanoparticles, their preparation methods, and applications. Background Technology

[0002] Triple-negative breast cancer (TNBC) is a type of breast cancer that is negative for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) in immunochemical staining. TNBC accounts for approximately 10%-20% of all breast cancer types and has a poor prognosis. Due to the lack of effective targeted therapies, traditional chemotherapy is the main clinical treatment, but it has significant toxic side effects. Therefore, there is an urgent need to investigate potential therapeutic targets and develop new treatment strategies.

[0003] Orphan receptor tyrosine kinase-like receptor 1 (ROR1) is a single-transmembrane protein belonging to the receptor tyrosine kinase (RTK) family. It plays a crucial role in developmental morphology by regulating cell proliferation, differentiation, migration, and survival. ROR1 is highly expressed in various hematologic malignancies and solid tumors, promoting tumor cell proliferation and metastasis by mediating the non-canonical Wnt signaling pathway. Due to its tumor-specific expression and potential functions, ROR1 has become a highly attractive target for immunotherapy.

[0004] Compared to other nanocarriers, lipid nanoparticles exhibit superior drug delivery capabilities and biocompatibility. To deliver drugs to specific tumor cells or tissues, antibody-modified lipid nanoparticles, as an active targeted drug delivery system, can increase drug distribution at the target site and minimize drug toxicity, thereby improving therapeutic efficacy and attracting widespread attention in the clinical treatment of cancer.

[0005] However, current active targeted lipid nanoparticle delivery systems for ROR1 still have shortcomings. For example, existing modification strategies often suffer from unstable antibody conjugation efficiency and poor uniformity of nanoparticle size after modification. Furthermore, some conjugation methods can affect the binding affinity of antibodies to ROR1, resulting in the target enrichment effect not meeting expectations. At the same time, research on ROR1-targeted delivery systems for TNBC is still relatively limited. A mature delivery system with high targeting specificity, low off-target toxicity, and good drug loading capacity has not yet been developed, which cannot meet the clinical needs for precision treatment of TNBC. Therefore, it is still necessary to develop more stable and efficient ROR1 antibody-modified lipid nanoparticle delivery systems to improve the treatment effect of triple-negative breast cancer. Summary of the Invention

[0006] The first aspect of the present invention is to provide a monoclonal antibody against ROR1 or an antigen-binding fragment thereof.

[0007] A second aspect of the present invention is to provide a fusion antibody.

[0008] A third aspect of the present invention aims to provide biological materials related to the monoclonal antibody or antigen-binding fragment thereof of the first aspect of the present invention or the fusion antibody of the second aspect of the present invention.

[0009] The fourth aspect of this invention is to provide a nanoparticle.

[0010] The fifth aspect of this invention aims to provide the application of the monoclonal antibody or antigen-binding fragment thereof of the first aspect of this invention, the fusion antibody of the second aspect of this invention, the biomaterial of the third aspect of this invention, or the nanoparticle of the fourth aspect of this invention.

[0011] The sixth aspect of this invention aims to provide a product.

[0012] To achieve the above objectives, the technical solution adopted by the present invention is as follows: In a first aspect, the present invention provides a monoclonal antibody against ROR1 or an antigen-binding fragment thereof, said monoclonal antibody or antigen-binding fragment thereof comprising a heavy chain and a light chain; The heavy chain includes a heavy chain variable region, which contains CDR-H1, CDR-H2 and CDR-H3 of the heavy chain variable region; The light chain includes a light chain variable region, which includes CDR-L1, CDR-L2 and CDR-L3 of the light chain variable region; According to the IMGT definition scheme: the amino acid sequences of CDR-H1, CDR-H2 and CDR-H3 of the heavy chain variable region are shown in SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5 respectively; the amino acid sequences of CDR-L1, CDR-L2 and CDR-L3 of the light chain variable region are shown in SEQ ID NO:6, RAN and SEQ ID NO:7 respectively.

[0013] In some embodiments of the present invention, the amino acid sequence of the heavy chain variable region is any one of A1)-A3): A1) As shown in SEQ ID NO:1; A2) An amino acid sequence with the same or similar function after one or more amino acids have been substituted, deleted or added to the amino acid sequence shown in SEQ ID NO:1. A3) An amino acid sequence that has 85% or more sequence identity with SEQ ID NO:1 and has the same or similar function.

[0014] In some embodiments of the present invention, the amino acid sequence of the heavy chain variable region is as shown in SEQ ID NO:1 or SEQ ID NO:8.

[0015] In some embodiments of the present invention, the amino acid sequence of the light chain variable region is any one of B1)-B3): B1) As shown in SEQ ID NO:2; B2) The amino acid sequence shown in SEQ ID NO:2 is modified by substitution, deletion or addition of one or more amino acids and has the same or similar function; B3) has an amino acid sequence that has 85% or more sequence identity with SEQ ID NO:2 and is functionally identical or similar.

[0016] In some embodiments of the present invention, the amino acid sequence of the light chain variable region is as shown in SEQ ID NO:2 or SEQ ID NO:9.

[0017] In some embodiments of the present invention, the monoclonal antibody or its antigen-binding fragment comprises at least one of a full-length antibody, Fab, Fab', F(ab')2, Fv or scFv.

[0018] In some embodiments of the present invention, the scFv includes a heavy chain variable region, a light chain variable region, and a linker peptide.

[0019] In some embodiments of the present invention, the linker peptide is a flexible linker.

[0020] In some embodiments of the present invention, the flexible linker amino acid sequence includes, but is not limited to, GSAS, (GGCAGCGCCAGC). n (GGCGGCGGCAGC) n (GGCGGCGGCGGCAGC) n YAPVDV, (GGGS) n (GGSG) n (GGGGS) n (G) n , where 1≤n≤5, and n is an integer.

[0021] In some embodiments of the present invention, the amino acid sequence of the scFv is as shown in SEQ ID NO:10 or SEQ ID NO:11.

[0022] A second aspect of the present invention provides a fusion antibody comprising a first domain and a second domain; The first domain is a monoclonal antibody or its antigen-binding fragment according to the first aspect of the present invention; The second domain has the effect of prolonging the in vivo half-life and / or binding to effector cells.

[0023] In some embodiments of the present invention, the second structural domain includes (but is not limited to): an immunoglobulin Fc region (such as the human immunoglobulin Fc region); and / or Serum albumin (such as human HSA) or fragments thereof, serum albumin-binding domains (such as anti-serum albumin antibodies, including nanobodies), polyethylene glycol, polyethylene glycol-liposome complexes, or combinations thereof; and / or Molecules that have an affinity for T cell surface molecules and / or are able to bind to surface molecules (such as CD3) present on T cells.

[0024] In some embodiments of the present invention, the human immunoglobulin Fc region includes mutations for altering Fc-mediated effector functions, the effector functions including one or more combinations of CDC activity, ADCC activity, and ADCP activity.

[0025] In some embodiments of the present invention, the immunoglobulin is selected from one or more combinations of IgG, IgA1, IgA2, IgD, IgE, and IgM.

[0026] In some embodiments of the present invention, the IgG is selected from one or more combinations of IgG1, IgG2, IgG3 or IgG4 subtypes.

[0027] In some embodiments of the present invention, the first structural domain is connected to the N-terminus or C-terminus of the second structural domain.

[0028] In some embodiments of the present invention, the first and second domains are hinged together or connected by a linker peptide.

[0029] In some embodiments of the present invention, the linker peptide is a flexible linker.

[0030] In some embodiments of the present invention, the heavy chain amino acid sequence of the fusion antibody is shown in SEQ ID NO:14, and the light chain amino acid sequence is shown in SEQ ID NO:13.

[0031] A third aspect of the invention provides biological materials relating to the monoclonal antibody or its antigen-binding fragment of the first aspect of the invention or the fusion antibody of the second aspect of the invention, said biological material being any one of a1)-a12): a1) A nucleic acid molecule encoding a monoclonal antibody or its antigen-binding fragment of the first aspect of the present invention or a fusion antibody of the second aspect of the present invention; a2) An expression cassette containing the nucleic acid molecule described in a1); a3) A recombinant vector containing the nucleic acid molecules described in a1); a4) A recombinant vector containing the expression cassette described in a2); a5) Recombinant microorganisms containing the nucleic acid molecules described in a1); a6) Recombinant microorganisms containing the expression cassette described in a2); a7) Recombinant microorganisms containing the recombinant vector described in a3); a8) Recombinant microorganisms containing the recombinant vector described in a4); a9) Transgenic cell lines containing the nucleic acid molecules described in a1); a10) Transgenic cell lines containing the expression cassette described in a2); a11) Transgenic cell lines containing the recombinant vector described in a3); a12) Transgenic cell lines containing the recombinant vector described in a4).

[0032] In some embodiments of the present invention, the transgenic animal cell line does not contain reproductive material.

[0033] In some embodiments of the present invention, the vector includes a promoter that is operatively linked to the nucleic acid molecule.

[0034] In some embodiments of the present invention, the vector is independently selected from non-pathogenic viral vectors and viral vectors.

[0035] In some embodiments of the present invention, the viral vector includes at least one of lentiviral vector, adenovirus vector, baculovirus vector, retrovirus vector, poxvirus vector, Sendai virus vector, and herpes simplex virus vector.

[0036] In some embodiments of the present invention, the non-viral vector includes at least one of plasmid vectors, cationic polymer vectors, chitosan, polyethyleneimine, nanoparticle vectors, and liposomes.

[0037] In some embodiments of the present invention, the vector is a plasmid vector, a phage particle, a viral vector, a cell vector, a bacteriophage, a sclerotium, an F sclerotium, or an artificial chromosome.

[0038] In some embodiments of the present invention, the plasmid vector may be an optional plasmid, and the viral vector may be an optional virus.

[0039] In some embodiments of the present invention, the cells include prokaryotic cells and eukaryotic cells; the cells are not new plant or animal varieties.

[0040] In some embodiments of the present invention, the prokaryotic cells include bacteria well known in the art, such as Escherichia coli, Streptomyces, and Bacillus subtilis, which are capable of expressing the target protein.

[0041] In some embodiments of the present invention, the eukaryotic cells include at least one of yeast cells, mammalian cells, plant cells, and insect cells.

[0042] A fourth aspect of the present invention provides a nanoparticle comprising lipid nanoparticles and an antibody modified on the surface of the lipid nanoparticles, wherein the antibody is a monoclonal antibody or an antigen-binding fragment thereof of the first aspect of the present invention or a fusion antibody of the second aspect of the present invention.

[0043] In some embodiments of the present invention, the lipid nanoparticles include phospholipids, structural lipids, and polymer-conjugated lipids.

[0044] In some embodiments of the present invention, the phospholipid is selected from at least one of dipalmitoylphosphatidylcholine, 1,2-dilinoleoyl-sn-glycerol-3-phosphate choline, 1,2-dimyristoyl-sn-glycerol-3-phosphate choline, 1,2-dioleoyl-sn-glycerol-3-phosphate choline, 1,2-dipalmitoyl-sn-glycerol-3-phosphate choline, 1,2-distearate-sn-glycerol-3-phosphate choline, and sphingomyelin; preferably dipalmitoylphosphatidylcholine.

[0045] In some embodiments of the present invention, the structural lipid is selected from at least one of cholesterol, coccosterol, sitosterol, ergosterol, campesterol, stigmasterol, phytosterol, tomatine, ursolic acid and α-tocopherol; preferably cholesterol.

[0046] In some embodiments of the present invention, the polymer-conjugated lipids include PEG-modified lipids.

[0047] In some embodiments of the present invention, the PEG-modified lipid is selected from at least one of PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic acid, PEG-modified ceramide, PEG-modified dialkylamine, PEG-modified diacylglycerol, and PEG-modified dialkylglycerol. PEG-modified lipids can be PEG-dioleoylglycerol (PEG-DOG), PEG-dimyristoylglycerol (PEG-DMG), PEG-dipalmitoylglycerol (PEG-DPG), PEG-dilinoleoylglycerol phosphatidylethanolamine (PEG-DLPE), PEG-dimyristoylglycerol phosphatidylethanolamine (PEG-DMPE), PEG-dipalmitoylglycerol phosphatidylethanolamine (PEG-DPPE), PEG-distearate glycerol (PEG-DSG), PEG-diacylglycerol (PEG-DAG, such as PEG-DMG, PEG-DPG and PEG-DSG), PEG-ceramide, PEG-distearate glycerol phosphate (PEG-DSPG), PEG-dioleoylglycerol phosphate ethanolamine (PEG-DOPE), 2-[(PEG)-2000]-N,N-bistetradecylacetamide or PEG-distearate phosphatidylethanolamine (PEG-DSPE) lipid or DSPE-PEG-NHS.

[0048] In some embodiments of the present invention, the molecular weight of PEG in the PEG-modified lipid is 2000-5000.

[0049] In some embodiments of the present invention, the mass ratio of the phospholipid, the structural lipid and the polymer-conjugated lipid is (3-6):1:(2-3); further, it is (4-6):1:(2-3); and even further, it is 5:1:2.

[0050] In some embodiments of the present invention, the lipid nanoparticles also include cytotoxins.

[0051] In some embodiments of the present invention, the cytotoxic agent is selected from at least one of topoisomerase inhibitors, MMAE, MMAF (Monomethyl auristatin F), SN-38, gemcitabine, maytansine alkaloids (such as Maytansine DM1, Maytansine DM4), kazimidic acid, MGBA (such as duocarmycin), doxorubicin, ricin, diphtheria toxin, or pyruvic acid SA; preferably MMAE.

[0052] In some embodiments of the present invention, lipid nanoparticles are prepared by a thin-film hydration method, which includes the following steps: dissolving phospholipids, structural lipids and polymer-conjugated lipids in chloroform, adding cytotoxins, reacting to obtain a lipid film; mixing the lipid film with water, ultrasonically hydrating to obtain lipid nanoparticles.

[0053] In some preferred embodiments of the present invention, the reaction conditions are rotary evaporation at 30-50°C for 20-40 minutes; further, rotary evaporation at 30-45°C for 25-35 minutes; and even further, rotary evaporation at 35-45°C for 30-35 minutes.

[0054] In some preferred embodiments of the present invention, the ultrasonic hydration time is 10-30 minutes; further, 15-30 minutes; and even further, 15-25 minutes.

[0055] In some embodiments of the present invention, the nanoparticles are prepared by the following steps: mixing lipid nanoparticles with an antibody and incubating them to obtain nanoparticles.

[0056] In some preferred embodiments of the present invention, the incubation conditions are: 400-500 rpm oscillation incubation for 10-30 hours; further, 420-480 rpm oscillation incubation for 15-30 hours; and even further, 440-460 rpm oscillation incubation for 20-25 hours.

[0057] A fifth aspect of the present invention provides the use of the monoclonal antibody or antigen-binding fragment thereof of the first aspect of the present invention, the fusion antibody of the second aspect of the present invention, the biomaterial of the third aspect of the present invention, or the nanoparticle of the fourth aspect of the present invention in b1)-b4): b1) To prepare drugs or preparations for the prevention and / or treatment of tumors; b2) Prepare reagents or kits for detecting tumors; b3) Inhibit the expression of tubulin; b4) Prepare reagents, kits or drugs to inhibit the expression of tubulin.

[0058] In some embodiments of the present invention, the tumors described in b1)-b2) include solid tumors or hematomas.

[0059] In some embodiments of the present invention, the solid tumor includes at least one of mesothelioma, liposarcoma, gastrointestinal stromal tumor (GIST), endometrioid carcinoma, breast cancer (such as triple-negative breast cancer), lung cancer (such as non-small cell lung cancer), lung adenocarcinoma, hepatocellular carcinoma, pancreatic cancer, ovarian cancer, colon cancer, and neuroblastoma.

[0060] In some embodiments of the present invention, the hematologic malignancy includes at least one of B-cell chronic lymphocytic leukemia (CLL), B-cell acute lymphoblastic leukemia (B-ALL), non-Hodgkin lymphoma (NHL), and myeloid hematologic malignancies.

[0061] The term "tumor treatment drug" as used in this invention refers to a drug that inhibits and / or treats tumors, and may include delaying and / or reducing the severity of tumor-related symptoms, further including alleviating existing tumor-related symptoms and preventing the occurrence of other symptoms, as well as reducing or preventing tumor metastasis, etc.

[0062] A sixth aspect of the present invention provides a product comprising a monoclonal antibody or antigen-binding fragment thereof according to the first aspect of the present invention, a fusion antibody according to the second aspect of the present invention, a biomaterial according to the third aspect of the present invention, or nanoparticles according to the fourth aspect of the present invention.

[0063] In some embodiments of the present invention, the product includes reagents, kits, and drugs.

[0064] In some embodiments of the present invention, the product has at least one of the following functions: prevention and / or treatment of tumors, detection of tumors, and inhibition of microtubule expression.

[0065] In some embodiments of the present invention, the medicament further includes pharmaceutically acceptable excipients.

[0066] The pharmaceutically acceptable excipients include at least one of the following: propellants, colorants, binders, disintegrants, fillers, lubricants, wetting agents, osmotic pressure regulators, stabilizers, flow aids, flavoring agents, preservatives, suspending agents, coating materials, fragrances, anti-adhesion agents, penetration enhancers, pH adjusters, buffers, plasticizers, surfactants, foaming agents, defoamers, thickeners, encapsulating agents, humectants, absorbents, diluents, flocculants and anti-flocculation agents, filter aids, and release inhibitors.

[0067] The pharmaceutically acceptable excipients mentioned above are generally recognized for use in this purpose and as inactive ingredients in the pharmaceutical preparation. Compilations of pharmaceutically acceptable excipients can be found in reference books such as the *Handbook of Pharmaceutical Excipients* (2nd edition, edited by A. Wade and PJ Weller; published by the American Pharmaceutical Association, Washington and The Pharmaceutical Press, London, 1994) and the *Pharmacopoeia of the People's Republic of China - List of Pharmaceutical Excipients*.

[0068] In some embodiments of the present invention, the dosage form of the drug includes one of the following: powder, tablet, granule, capsule, sustained-release, solution, dry suspension, effervescent tablet, emulsion, suspension, syrup, drops, and chewable tablet.

[0069] In some embodiments of the present invention, the administration of the drug includes administration via the gastrointestinal tract or non-gastrointestinal route.

[0070] In some embodiments of the present invention, the gastrointestinal administration includes one of oral administration, sublingual administration, and rectal administration.

[0071] In some embodiments of the present invention, the non-gastrointestinal administration includes one of intravenous injection, subcutaneous injection, and mucosal administration.

[0072] The beneficial effects of this invention are: This invention provides an anti-ROR1 monoclonal antibody or its antigen-binding fragment, comprising a murine anti-ROR1 monoclonal antibody and a single-chain antibody, and a humanized anti-ROR1 monoclonal antibody and a single-chain antibody. The murine anti-ROR1 monoclonal antibody is obtained using hybridoma technology, and the heavy chain variable region and light chain variable region of the humanized antibody are derived from the murine anti-ROR1 monoclonal antibody. The humanized variable region sequence is constructed onto a human IgG1 antibody backbone to obtain a humanized anti-ROR1 monoclonal antibody (Hu 3-H10-F4 IgG). This antibody exhibits good affinity and endocytic ability.

[0073] Furthermore, this invention utilizes a thin-film hydration method to prepare ROR1 antibody-modified lipid nanoparticles Lip(MMAE)-Hu3, with the inner layer encapsulating the cytotoxin MMAE and the outer lipid layer modified with Hu3-H10-F4 IgG antibody. These nanoparticles can bind to the triple-negative breast cancer MDA-MB-231 cell line and exhibit significant anti-tumor effects against xenografted triple-negative breast cancer cells in mice, while simultaneously inhibiting the expression of intracellular tubulin. Attached Figure Description

[0074] The present invention will be further described below with reference to the accompanying drawings and embodiments, wherein: Figure 1 To detect the fusion titer of mouse anti-human ROR1 hybridoma cell lines, green was used to indicate the selected hybridoma cell lines for subsequent monoclonal culture and antibody purification.

[0075] Figure 2 To re-examine the endocytosis efficiency of mouse-derived anti-human ROR1 hybridoma cell lines. Yellow represents the control HT-29 cell line, red represents the fluorescence distribution of the 4℃ culture group, and blue represents the fluorescence distribution of the 37℃ endocytosis experimental group.

[0076] Figure 3The results show the purification and activity identification of the murine anti-human ROR1 monoclonal antibody. (A) shows the SDS-PAGE results. The murine anti-human ROR1 monoclonal antibody was purified by protein A. Lane 1: 2-A6-F8, Lane 2: 3-H10-F4, Lane 3: 21-H6-D4, Lane 4: 26-D9-H11, Lane 5: 25-A9-G3, Lane 6: 18-D2-D3, Lane 7: 2-B12-E8, Lane 8: 28-G6-C2, Lane 9: 19-H4-E2, Lane 10: 11-H7-E8, Lane 11: 11-H8-B8, Lane 12: 22-A4-H11, Lane 13: 27-F9-E7; (B) is the ELISA result of mouse anti-human ROR1 monoclonal antibody; (C) is the ELISA result of competitive combination of mouse anti-human ROR1 monoclonal antibodies.

[0077] Figure 4 Expression, purification, and activity assay of single-chain anti-human ROR1 monoclonal antibody (scFv). (A) shows the SDS-PAGE results of the purified anti-human ROR1 single-chain antibody, lane 1: 3-H10-F4 scFv, lane 2: Hu 3-H10-F4 scFv; (B) shows the ELISA results of murine anti-human ROR1 single-chain antibody and humanized anti-human ROR1 single-chain antibody.

[0078] Figure 5 Expression, purification, and activity assay of humanized anti-human ROR1 monoclonal antibody Hu 3-H10-F4 IgG. (A) shows the SDS-PAGE results of Hu 3-H10-F4 IgG; (B) shows the ELISA results of humanized Hu 3-H10-F4 IgG and mouse anti-ROR1 monoclonal 3-H10-F4.

[0079] Figure 6 Affinity assay for humanized anti-human ROR1 antibody Hu3-H10-F4 IgG.

[0080] Figure 7 Cell binding and endocytosis capabilities of humanized anti-human ROR1 intact IgG antibodies were measured. (A) shows the binding ability of Hu 3-H10-F4 IgG antibody to triple-negative breast cancer MDA-MB-231 and colon cancer cell line HT-29, as detected by flow cytometry; (B) shows the endocytosis of Hu 3-H10-F4 IgG in MDA-MB-231 cells.

[0081] Figure 8This is a schematic diagram of the synthesis of antibody-modified lipid nanoparticles Lip(MMAE)-Hu3.

[0082] Figure 9 Characterization and affinity assay of antibody-modified lipid nanoparticles Lip(MMAE)-Hu3. (A) shows the electron microscopy results of Lip(MMAE)-Hu3; (B) shows the size distribution of Lip(MMAE)-Hu3; and (C) shows the affinity assay of antibody-modified lipid nanoparticles Lip(MMAE)-Hu3 for ROR1 antigen.

[0083] Figure 10 The target uptake and penetration of antibody-modified lipid nanoparticles Lip(MMAE)-Hu3 in MDA-MB-231 cells are shown. (A) shows the fluorescence co-localization of Lip(MMAE)-Hu3; (B) shows the penetration ability of Lip(MMAE)-Hu3 in 3D cell spheroids.

[0084] Figure 11 The results show the in vitro killing effect of Lip(MMAE)-Hu3 on the MDA-MB-231 triple-negative breast cancer cell line. Different concentrations of MMAE were used.

[0085] Figure 12 This study investigates the antitumor effect of Lip(MMAE)-Hu3 on triple-negative breast cancer xenograft mice. In Figure (A), the tumor growth curve of MDA-MB-231 is shown, and the tumor volume is calculated using the formula 0.5 × length × width. 2 (B) is the curve of mouse weight change.

[0086] Figure 13 The results of microtubule staining on tumor tissue sections. Detailed Implementation

[0087] The following will describe the concept and technical effects of the present invention clearly and completely with reference to embodiments, so as to fully understand the purpose, features and effects of the present invention. Obviously, the described embodiments are only some embodiments of the present invention, not all embodiments. Other embodiments obtained by those skilled in the art based on the embodiments of the present invention without creative effort are all within the scope of protection of the present invention.

[0088] Unless otherwise specified in the examples, the procedures should be performed under standard conditions or conditions recommended by the manufacturer. Reagents or instruments whose manufacturers are not specified are all commercially available products.

[0089] The features and performance of the present invention will be further described in detail below with reference to embodiments.

[0090] Example 1: Preparation of a hybridoma cell line expressing mouse anti-human ROR1 (1) Fusion valence test Use human ROR1 antigen (amino acid sequence: QETELSVSAELVPTSSWNISSELNKDSYLTLDEPMNNITTSLGQTAELHCKVSGNPPPTIRWFKNDAPVVQEPRRLSFRSTIYGSRLRIRNLDTTDTGYFQCVATNGKEVVSSTGVLFVKFGPPPTASPGYSDEYEEDGFCQPYRGIACARFIGNRTVYMESLHMQGEIENQITAAFTMIGTS SHLSDKCSQFAIPSLCHYAFPYCDETSSVPKPRDLCRDECEILENVLCQTEYIFARSNPMILMRLKLPNCEDLPQPESPEAANCIRIGIPMADPINKNHKCYNSTGVDYRGTVSVTKSGRQCQPWNSQYPHTHTFTALRFPELNGGHSYCRNPGNQKEAPWCFTLDENFKSDLCDIPACDSKDSKEKNKMEILY, SEQ ID NO:15) Balb / c mice were immunized. After fusion, the spleens of the mice were removed, and spleen cells were isolated and co-cultured with NS-1 myeloma cell line in logarithmic growth phase. The cells were serially diluted into 96-well cell culture plates and cultured in HAT selection medium. One week later, ELISA was used to detect the expression of anti-ROR1 monoclonal antibody in the fusion cells. A total of 30 96-well cell culture plates were analyzed. Figure 1 ).

[0091] (2) Subcloning retest Positive clones were selected for amplification and preservation, and hybridoma antibody supernatant was used for endocytosis assays for confirmation. HT29 target cells were prepared, and 200 mL of hybridoma supernatant was added. After incubation at 4°C for 30 minutes, the antibody-containing supernatant was removed, and the cells were washed three times with pre-chilled PBS. The cells were divided into two groups and incubated at 4°C and 37°C for 4 hours respectively. Immediately after incubation, PBS on ice was added to terminate endocytosis. After centrifugation, the cells were resuspended in 100 mL of PBS. PE-labeled anti-mouse IgG was added, and after incubation at 4°C for 30 minutes, flow cytometry analysis was performed. The endocytosis level of the cell surface-bound antibody was calculated as follows: tx time point MFI% = MFI of the 37°C incubated sample / MFI of the 4°C incubated control sample; tx time point endocytosis percentage = 100% - tx time point MFI.

[0092] like Figure 2 A total of 14 hybridoma cell lines expressing mouse-derived anti-human ROR1 monoclonal antibodies were screened.

[0093] Example 2: Expression, purification, and activity detection of mouse-derived anti-human ROR1 monoclonal antibody (1) Expression and purification of mouse-derived anti-human ROR1 monoclonal antibody Hybridoma cell lines containing the anti-human ROR1 monoclonal antibody screened in Example 1 were cultured to express and purify the mouse-derived anti-human ROR1 monoclonal antibody. Specifically, cells were placed in DMEM medium with 20% FBS and 1% PS and cultured at 37°C. The cells were semi-adherent, and the passage ratio was 1:3. The cell number reached 1×10⁶ cells / year. 7 Afterwards, the cells were digested with trypsin, centrifuged at 1300 rpm for 3 minutes, and the supernatant was discarded. The cells were then cultured in serum-free hybridoma cell culture medium at 37°C for 5 days. After centrifugation, the supernatant was filtered through a 0.45 mm filter membrane to purify the mouse anti-human ROR1 monoclonal antibody, yielding 10 antibodies. Further purification was performed, with the following specific steps: Protein A packing material (purchased from GE Healthcare, catalog number 17-1279-03) was added to the protein purification column. After washing with PBS, the supernatant was added to the protein purification column. The supernatant passed through the packing material under gravity, and the antibody Fc structure bound to Protein A. This step was repeated twice. After washing with PBS, the protein was eluted with 1 mL of 50 mg Macetic acid (pH=3) and neutralized with 0.25 mL of 1 M Tris-HCl (pH=8). The purified protein was identified by SDS-PAGE.

[0094] like Figure 3 As shown in Figure A, the mouse-derived anti-human ROR1 monoclonal antibody was successfully expressed and purified, and the protein band size was correct.

[0095] (2) Activity detection of mouse-derived anti-human ROR1 monoclonal antibody The binding affinity of mouse monoclonal antibody to ROR1 antigen was detected by ELISA. 50 ng of ROR1 antigen was plated in 96-well plates. The primary antibody was purified mouse anti-human ROR1 monoclonal antibody, and the secondary antibody was HRP-labeled goat anti-mouse antibody. The specific steps of the ELISA were as follows: Pack the plate with 50 ng ROR1 antigen and incubate overnight at 4°C; block with 2.5% skim milk powder at 37°C for 1 hour, then wash 3 times with PBST; incubate with primary antibody at 37°C for 1 hour; wash 3 times with PBST, then incubate with secondary antibody at 37°C for 45 minutes; after washing 3 times with PBST, add 100 mL TMB chromogenic solution, and after 10 minutes add 100 mL stop solution. Read the value at 450 nm using an ELISA reader.

[0096] The results are as follows Figure 3As shown in Figure B, murine anti-human ROR1 monoclonal antibodies can bind to the ROR1 antigen, but with varying binding abilities. Through competitive ELISA, the 21-H6-D4, 2-B12-E8, and 25-A9-G3 monoclonal antibodies bind to the same ROR1 epitope, while the remaining antibodies bind to a different epitope. Figure 3 (C)

[0097] Example 3: Amplification and Sequencing Results Analysis of the Variable Region Sequence of Mouse-Derived Anti-Human ROR1 Monoclonal Antibody Prepare 1×10 of each 7 Total RNA was extracted from hybridoma cell lines expressing murine anti-human ROR1 monoclonal antibody. The specific RNA extraction steps were as follows: The hybridoma cell lines were centrifuged to remove the supernatant. 1 mL of Trizol reagent was added and the mixture was pipetted and mixed. 240 mL of chloroform was added, and the mixture was vigorously shaken and incubated at room temperature for 10 minutes. Then, the cells were centrifuged at 13000×g at 4°C for 15 minutes. 450 mL of the upper aqueous phase was transferred to a new EP tube, and 450 mL of ice-cold isopropanol was added. The mixture was inverted several times to mix, and the cells were incubated on ice for 10 minutes. Then, the cells were centrifuged at 13000×g at 4°C for 10 minutes. The supernatant was discarded, and the RNA precipitate was washed with 75% ethanol (prepared with DEPC water) by inverting. The cells were centrifuged at 13000×g at 4°C for 5 minutes. The ethanol washing step was repeated. The cells were inverted to remove the supernatant, air-dried for 5 minutes, and then the RNA was dissolved in 40 mL of RNase-free water. The concentration and mass of the RNA were measured.

[0098] Total RNA extracted was reverse transcribed into cDNA using a reverse transcription kit, and the product was stored at -80℃. Primers were designed based on the sequences of the constant region and the backbone region of the variable region of the antibody. The variable region sequence of the murine anti-human ROR1 monoclonal antibody in the hybridoma cell line was cloned from the cDNA sequence of the hybridoma cell line. The reaction program was: 92℃, 5 min; 94℃, 20 s; 54℃, 30 s; 72℃, 1 min; 35 cycles, 72℃, 5 min. PCR products with clear bands were selected for sequencing using 2% agarose gel electrophoresis. The heavy chain and light chain variable regions of the murine anti-human monoclonal antibody (3-H10-F4) are shown in Table 1.

[0099] Table 1. Amino acid sequences of the heavy and light chain variable regions of mouse-derived anti-human ROR1 monoclonal antibodies.

[0100] The CDR region of the above-mentioned murine anti-human ROR1 monoclonal antibody was analyzed, and the CDR region was identified and annotated using the IMGT numbering system. The specific results are shown in Table 2.

[0101] Table 2. CDR sequence analysis of murine anti-human ROR1 monoclonal antibodies

[0102] Example 4: Humanization of the variable region of a mouse-derived anti-human ROR1 monoclonal antibody Humanization of the mouse sequence was performed using Discovery Studio software. The amino acid sequence of the antibody from Example 3 was input, and the software constructed a homologous 3D model based on existing sequences in the database, analyzing the CDR and framework regions of the heavy and light chains. Based on existing sequences in the database, the mouse CDR sequence was transferred to a human template, and a reversion mutation was performed on the human framework. The specific humanized Hu 3-H10-F4 IgG sequence is shown in Table 3.

[0103] Table 3. Humanized variable region sequences of mouse anti-human ROR1 monoclonal antibodies

[0104] Example 5: Construction and activity assay of single-chain antibodies against mouse-derived and humanized anti-human ROR1 monoclonal antibodies. In this embodiment, the single-chain antibody (scFv) is composed of the heavy chain variable region and the light chain variable region of the murine anti-human ROR1 antibody and the humanized anti-human ROR1 monoclonal antibody, respectively, and the heavy chain variable region and the light chain variable region are linked by the linker peptide (GGGGS)3.

[0105] The amino acid sequence of the mouse-derived 3-H10-F4 scFv is as follows: EVKLVESGGGFVKPGGSLKLSCAASGFTFSRYAMSWVRQTPEKRLEWVASISRGGSPYYLDSVKGRFTISRDNDRNILYLQMSSLRSEDTAMYYCARGPSTATDYVMDCWGQGTSVTVSS GGGGSGGGGSGGGGS DILMTQSPSSMYTSLGERVTITCKASQDINSYLSWFQQKPGKSPKTLIFRANRLVDGVPSRFSGSGSGQDYSLTISSLEYEDMGIYYCLQYDEFPYTFGGGTKLEIK (SEQ ID NO:10), the underlined part is the linker peptide.

[0106] The amino acid sequence of the humanized Hu 3-H10-F4 scFv is as follows: EVQLVESGGGLVKPGGSLRLSCAASGFTFSRYAMSWVRQAPGKGLEWVASISRGGSPYYLDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGPSTATDYVMDCWGQGTLVTVSS GGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCKASQDINSYLSWFQQKPGKAPKTLIFRANRLVDGVPSRFSGSGSGQDYTLTISSLQPEDFATYYCLQYDEFPYTFGQGTKLEIK (SEQ ID NO:11), the underlined part is the linker peptide.

[0107] The scFv sequence was constructed into the pComb3X vector plasmid and a prokaryotic expression system was used. E. coli The specific steps for expressing single-chain antibodies are as follows: 1) Preparation of competent HB2151 strain: Inoculate HB2151 strain into antibiotic-free agarose solid plates and incubate overnight at 37°C. Pick a single clone of the strain and add it to 3 mL of antibiotic-free 2YT liquid medium, and incubate overnight at 37°C with shaking. Inoculate the strain into 100 mL of fresh 2YT medium at a ratio of 1:100, and incubate at 37°C and 220 rpm until OD. 600 =0.6. Incubate the culture medium on ice for 10 minutes, centrifuge at 3000×g for 10 minutes at 4℃. Discard the supernatant, add 4 mL of pre-chilled 0.1 mol / L CaCl2 solution containing 15% glycerol to suspend the cells, incubate on ice for 10 minutes, aliquot into pre-chilled sterile EP tubes, and store at -80℃. 2) Transform the plasmid into competent HB2151 strains. Add 1 mg of plasmid to 50 mL of competent HB2151 bacteria, incubate on ice for 30 minutes, heat shock at 42℃ for 90 seconds, incubate on ice, plate onto ampicillin plates, and incubate overnight at 37℃. 3) Induce expression of single-chain antibodies. Pick single colonies and place them in 50 mL of 2YT liquid medium containing ampicillin resistance and 1% glucose, incubate at 37℃ for 220 rpm until OD. 600 =0.6. IPTG was added to a final concentration of 0.5 mM to induce expression, and the culture was continued overnight at 30℃ and 180 rpm. After induction, the bacterial culture was centrifuged, the supernatant was discarded, and the cells were resuspended in 30 mL of PBS. Polymyxin B solution was added to a final concentration of 0.5 M, and the culture was incubated at 37℃ with shaking for 1 hour. After centrifugation, the supernatant was collected, filtered through a 0.45 mm filter to remove impurities, and NaCl and imidazole were added to a final concentration of 300 mM. Purification was performed using Ni-NTA, utilizing the HIS protein tag on the antibody. The specific steps were as follows: nickel column packing was added to the protein purification column, washed with PBS, and the treated supernatant was added to the purification column. Under gravity, the HIS tag on the protein could bind to nickel ions as it passed through the packing. This step was repeated twice. After washing the column with washing buffer (18 mM imidazole), elution was performed using 100 mM imidazole buffer. The purified protein was identified using SDS-PAGE.

[0108] like Figure 4As shown in Figure A, the SDS-PAGE results show that the single-chain antibody was successfully expressed and purified.

[0109] ROR1 antigen was coated onto an ELISA plate and incubated overnight at 4°C. After blocking, the plate was incubated with serially diluted single-chain antibodies at 37°C for 1 hour. The secondary antibody was HRP-labeled HIS antibody, and the plate was incubated at 37°C for 45 minutes. ELISA results showed that the binding ability of the humanized 3-H10-F4 single-chain antibody was superior to that of the murine 3-H10-F4 single-chain antibody. Figure 4 (B)

[0110] Example 6 Construction and activity detection of humanized anti-human ROR1 intact IgG antibody The light chain variable region and heavy chain variable region of Hu 3-H10-F4 were respectively combined with the light chain constant region of human IgG1 (amino acid sequence: TVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC, SEQ ID). NO:12) and heavy chain constant region (ASTKGPSVFPLAPSSKSGSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK, SEQ ID NO:16) is connected to the B3.1 expression vector. After the plasmid was correctly sequenced by the company, it was transformed into TOP10 competent bacterial strains, plated on ampicillin-resistant solid plates, and incubated overnight at 37°C. Single colonies were picked and added to 50 mL of 2YT liquid medium containing ampicillin, and incubated overnight at 37°C. The supernatant was discarded after centrifugation, and endotoxin-free plasmids were extracted.

[0111] Transient transfection of 293F cells to express IgG antibody was performed. The specific steps were as follows: Prepare 293F cells at a density of 1×10⁻⁶ cells / cells. 6 / mL, cultured in 30 mL of fresh 293F medium. Prepare (a) solution: Add 30 mg of Hu 3-H10-F4 IgG plasmid to 1.5 mL of sterile PBS. (b) Solution: Add 120 mg of PEI 4W transfection reagent to 1.5 mL of sterile PBS. After incubating solutions (a) and (b) at room temperature for 5 minutes each, mix and incubate at room temperature for 10 minutes. Add the mixture dropwise to 293F cells and incubate with shaking at 37°C for 7 days. Collect the supernatant and purify the antibody using protein A resin.

[0112] SDS-PAGE results showed that the humanized anti-human ROR1 intact IgG1 antibody Hu 3-H10-F4 IgG band was clean and of the correct size. Figure 5 (A). ELISA results showed that (the coating antigen was ROR1, the primary antibodies were murine anti-ROR1 monoclonal antibody and humanized anti-human ROR1 monoclonal antibody, and the secondary antibody was HRP-labeled goat anti-human antibody), the binding ability of the humanized anti-human ROR1 intact IgG1 antibody Hu 3-H10-F4 IgG was superior to that of the murine anti-human ROR1 monoclonal antibody 3-H10-F4. Figure 5 (B)

[0113] The light chain amino acid sequence of the humanized anti-human ROR1 intact IgG1 antibody Hu 3-H10-F4 IgG is DIQMTQSPSSLSASVGDRVTITCKASQDINSYLSWFQQKPGKAPKTLIFRANRLVDGVPSRFSGSGSGQDYTLTISSLQPEDFATYYCLQYDEFPYTFGQGTKLEIKTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID) NO:13); The heavy chain amino acid sequence is EVQLVESGGGLVKPGGSLRLSCAASGFTFSRYAMSWVRQAPGKGLEWVASISRGGSPYYLDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGPSTA TDYVMDCWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVE PKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIE KTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO:14).

[0114] Example 7: Detection of the affinity of Hu 3-H10-F4 IgG antibody Biomembrane interferometry (BLI) was used to detect the interaction between antigen and antibody, i.e., to detect antibody affinity. The specific experimental steps of BLI are as follows: The proA sensor protein A was immersed in a buffer (PBS with 0.02% Tween and 0.1% BSA) for 10 minutes. The Hu 3-H10-F4 IgG antibody was diluted with the buffer to a concentration of 100 nM. The ROR1 antigen was serially diluted to concentrations of 50 nM, 25 nM, 12.5 nM, 6.25 nM, and 3.13 nM.

[0115] Specific test results are as follows: Figure 6 As shown, the KD value is 1.67 × 10⁻⁶. -8 M.

[0116] Example 8: Tumor cell binding ability and endocytosis of Hu 3-H10-F4 IgG antibody (1) The binding ability of Hu 3-H10-F4 IgG antibody to tumor cells The binding affinity of Hu 3-H10-F4 IgG antibody to the triple-negative breast cancer cell line MDA-MB-231 and the colon cancer cell line HT-29 was detected by flow cytometry. The cells were cultured in 1640 medium containing 5% FBS and 1% PS, and after three passages, 1×10⁶ cells were collected. 6 Cells were analyzed by flow cytometry. They were divided into a control group and a Hu 3-H10-F4 IgG antibody group. After incubation at 4°C for 1 hour, the cells were washed three times with PBS, and Alexa-647-labeled goat anti-human antibody was added as a secondary antibody. The cells were incubated at 4°C for 30 minutes, washed with PBS, and then analyzed by flow cytometry.

[0117] The results are as follows Figure 7 As shown in Figure A, the Hu 3-H10-F4 IgG antibody can bind to the triple-negative breast cancer cell line MDA-MB-231 and the colon cancer cell line HT-29.

[0118] (2) The endocytic ability of Hu 3-H10-F4 IgG antibody in triple-negative breast cancer cell lines The endocytic capacity of the Hu 3-H10-F4 IgG antibody was detected by flow cytometry, using the same method as in Example 1. The target cells were the triple-negative breast cancer cell line MDA-MB-231, and goat anti-human antibody labeled with Alexa-647 was used as the secondary antibody.

[0119] The results showed that the Hu 3-H10-F4 IgG antibody had good endocytic ability in MDA-MB-231 cells. Figure 7 (B)

[0120] Example 9 Preparation of antibody-modified lipid nanoparticles Lip(MMAE)-Hu3 Antibody-modified lipid nanoparticles Lip(MMAE)-Hu3 were prepared using a thin-film hydration method (flow diagram shown in Figure 1). Figure 8 As shown), the details are as follows: Dissolve 5 mg dipalmitoylphosphatidylcholine (DPPC), 1 mg cholesterol, and 2 mg DSPE-PEG5000-NHS in 5 mL of chloroform. Add 100 mL of monomethylaurestatin E (MMAE) chloroform solution (1 mg / mL). Evaporate using a rotary evaporator at 40 °C for 30 minutes to form a lipid film. Add 5 mL of ultrapure water and perform probe-type ultrasonic hydration for 10-20 minutes at an ultrasonic power of 20-40 kHz to obtain an aqueous solution of Lip (MMAE).

[0121] Approximately 100 mg of Hu 3-H10-F4 IgG antibody was added to the prepared Lip(MMAE) solution, and the mixture was incubated at room temperature with shaking at 450 rpm for 24 hours. Unbound antibody was removed using a dialysis bag (MW: 300 kDa) to obtain Lip(MMAE)-Hu3 antibody-modified lipid nanoparticles. Protein concentration was detected using the BCA method.

[0122] Example 10 Characterization and affinity assay of antibody-modified lipid nanoparticles Lip(MMAE)-Hu3 (1) Characterization of Lip(MMAE)-Hu3 antibody-modified lipid nanoparticles The morphology of Lip(MMAE)-Hu3 antibody-modified lipid nanoparticles was observed using transmission electron microscopy. The size distribution of the Lip(MMAE)-Hu3 antibody-modified lipid nanoparticles was detected using dynamic light scattering.

[0123] The morphology of the lipid nanoparticles modified with Lip(MMAE)-Hu3 antibody is as follows: Figure 9 As shown in Figure A, the size distribution is as follows: Figure 9 As shown in B.

[0124] (2) Affinity of Lip(MMAE)-Hu3 antibody-modified lipid nanoparticles The affinity of the Lip(MMAE)-Hu3 antibody-modified lipid nanoparticles was detected using BLI. The method was the same as in Example 7.

[0125] Specific results are as follows Figure 9 As shown in C, the KD value is 1.70 × 10⁻⁶. -8 (M) has an affinity for the ROR1 antigen comparable to that of the Hu 3-H10-F4 IgG antibody alone.

[0126] Example 11 Cell-targeted uptake and penetration of antibody-modified lipid nanoparticles Lip(MMAE)-Hu3 (1) Cellular targeted uptake of lipid nanoparticles modified with Lip(MMAE)-Hu3 antibody Cellular uptake of Lip(MMAE)-Hu3 antibody-modified lipid nanoparticles was analyzed using fluorescence colocalization. Triple-negative breast cancer cell line MDA-MB-231 was seeded into confocal culture dishes at 1–2 × 10⁻⁶ cm⁻¹. 5 Cells were incubated in 1 mL dishes for 24 hours to form a lipid film. Then, 1–3 μL of Lip(MMAE)-Hu3 (RhB: 2 mg / mL) dissolved in Rhodamine B (RhB) was added. After co-incubation for 12 hours, cells were washed three times with PBS, fixed with 4% paraformaldehyde for 30 minutes, permeabilized with 0.25% Triton X-100 for 25 minutes, blocked with 2.5% BSA for 2 hours, and then incubated with Alexa-647-labeled goat anti-human antibody for 1 hour. After staining cell nuclei with DAPI, the cell-targeted uptake and distribution of Lip(MMAE)-Hu3 antibody-modified lipid nanoparticles were observed using laser confocal microscopy.

[0127] The results are as follows Figure 10 Confocal fluorescence imaging results showed that MDA-MB-231 tumor cells treated with Lip(RhB)-Hu3 exhibited stronger fluorescence signals after incubation, further confirming the specific binding mediated by Hu3-H10-F4 IgG.

[0128] (2) Cell sphere penetration assay mediated by Hu 3-H10-F4 IgG antibody Approximately 3000 triple-negative breast cancer MDA-MB-231 cells were seeded into ultra-low adsorption 96-well plates and centrifuged at 300×g for 5 minutes. After culturing at 37℃ for 7 days, 3D tumor cell spheres were formed. Following the same method as (1), Lip(MMAE / RhB) and Lip(MMAE / RhB)-Hu3 (MMAE: 1 mg / mL, RhB: 2 mg / mL, Hu3-H10-F4 IgG: 10 mg / mL) were added to the 3D cell spheres respectively. After co-incubation for 48 hours, the fluorescence distribution of RhB at different depths of the cell spheres was detected by confocal microscopy to evaluate the penetration depth of antibody-modified lipid nanoparticles in the 3D tumor cell spheres.

[0129] The results are as follows Figure 10 The penetration depth of Lip(MMAE+RhB)-Hu3 was significantly higher than that of Lip(MMAE+RhB), demonstrating that Hu3-H10-F4 IgG antibody modification can significantly enhance the penetration ability of liposomes.

[0130] Example 12: Detection of the in vitro killing effect of Lip(MMAE)-Hu3 on triple-negative breast cancer cells The triple-negative breast cancer cell line MDA-MB-231 was seeded into 96-well plates (2.5-3 × 10⁻⁶). 4 After culturing at 37°C for 24 hours, Lip(MMAE) and Lip(MMAE)-Hu3 containing different concentrations of MMAE (60, 125, 250, 500 and 1000 ng / mL) were added to 96-well plates and incubated for a total of 12 hours. Then, 100 mL of CCK-8 solution was added to each well and incubated for another 2 hours. The absorbance at 450 nm was then read using a multi-mode microplate reader.

[0131] The results are as follows Figure 11 As shown, Hu 3-H10-F4 IgG can mediate targeted cell killing.

[0132] Example 13: Detection of the in vivo killing effect of Lip(MMAE)-Hu3 on triple-negative breast cancer cells. MDA-MB-231 xenograft mouse model was constructed by subcutaneous injection of 1×10-1 of these cells. 6 Treatment began 22 days after injection, with mice receiving PBS, Lip(MMAE) or Lip(MMAE)-Hu3 via tail vein injection at a concentration of 40 mg / mL, 100 mL per mouse. Treatment lasted for two weeks, with tumor volume and mouse weight measured every other day.

[0133] According to the results Figure 12 As shown, the tumor volume in the antibody-modified lipid nanoparticle (Lip(MMAE)-Hu3) treatment group was significantly smaller than that in the Lip(MMAE) control group, demonstrating a targeted anti-tumor effect in MDA-MB-231 xenograft mice. Simultaneously, there was no significant and rapid change in mouse body weight, indicating that the antibody-modified lipid nanoparticles have high therapeutic safety.

[0134] Example 14: Lip(MMAE)-Hu3 inhibits microtubule expression. To evaluate the MMAE-mediated microtubule inhibition effect, tumor tissues from each group (derived from Example 13) were sectioned, fixed, permeabilized, and blocked. The sections were then incubated overnight at 4°C with a primary microtubule antibody (Mouse monoclonal antibody to beta-Tubulin, purchased from Affinity Biosciences, catalog number T0023). After washing with PBS, the sections were incubated for 2 hours at room temperature with FITC-labeled goat anti-mouse antibody. Cell nuclei were stained with DAPI and observed using a laser confocal microscope.

[0135] The results are as follows Figure 13 As shown, laser confocal microscopy revealed the expression of tubulin that was targeted and inhibited by Lip(MMAE)-Hu3.

[0136] The embodiments of the present invention have been described in detail above with reference to the accompanying drawings. However, the present invention is not limited to the above embodiments, and various changes can be made within the scope of knowledge possessed by those skilled in the art without departing from the spirit of the present invention. Furthermore, the embodiments of the present invention and the features thereof can be combined with each other unless otherwise specified.

Claims

1. A monoclonal antibody against ROR1 or its antigen-binding fragment, characterized in that, The monoclonal antibody or its antigen-binding fragment comprises a heavy chain and a light chain; The heavy chain includes a heavy chain variable region, which contains CDR-H1, CDR-H2 and CDR-H3 of the heavy chain variable region; The light chain includes a light chain variable region, which includes CDR-L1, CDR-L2 and CDR-L3 of the light chain variable region; According to the IMGT definition scheme: the amino acid sequences of CDR-H1, CDR-H2 and CDR-H3 of the heavy chain variable region are shown in SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5 respectively; the amino acid sequences of CDR-L1, CDR-L2 and CDR-L3 of the light chain variable region are shown in SEQ ID NO:6, RAN and SEQ ID NO:7 respectively.

2. The monoclonal antibody or its antigen-binding fragment according to claim 1, characterized in that, The amino acid sequence of the heavy chain variable region is any one of A1)-A3): A1) As shown in SEQ ID NO:1; A2) An amino acid sequence with the same or similar function after one or more amino acids have been substituted, deleted or added to the amino acid sequence shown in SEQ ID NO:

1. A3) An amino acid sequence that has 85% or more sequence identity with SEQ ID NO:1 and has the same or similar function; Preferably, the amino acid sequence of the light chain variable region is any one of B1)-B3): B1) As shown in SEQ ID NO:2; B2) The amino acid sequence shown in SEQ ID NO:2 is modified by substitution, deletion or addition of one or more amino acids and has the same or similar function; B3) has an amino acid sequence that has 85% or more sequence identity with SEQ ID NO:2 and is functionally identical or similar.

3. The monoclonal antibody or its antigen-binding fragment according to claim 1 or 2, characterized in that, The monoclonal antibody or its antigen-binding fragment comprises at least one of a full-length antibody, Fab, Fab', F(ab')2, Fv or scFv; Preferably, the scFv includes a heavy chain variable region, a light chain variable region, and a linker peptide; Preferably, the linker peptide is a flexible linker; Preferably, the amino acid sequence of the flexible linker includes, but is not limited to, GSAS, (GGCAGCGCCAGC). n (GGCGGCGGCAGC) n (GGCGGCGGCGGCAGC) n YAPVDV, (GGGS) n (GGSG) n (GGGGS) n (G) n , where 1≤n≤5, and n is an integer; Preferably, the amino acid sequence of the scFv is as shown in SEQ ID NO:10 or SEQ ID NO:

11.

4. A fusion antibody, comprising a first domain and a second domain; The first domain is any one of the monoclonal antibodies or antigen-binding fragments thereof according to claims 1-3; The second domain has the effect of prolonging the in vivo half-life and / or has the effect of binding to effector cells; Preferably, the second structural domain includes: Immunoglobulin Fc region; and / or Serum albumin or fragments thereof, domains that bind to serum albumin, polyethylene glycol, polyethylene glycol-liposome complexes, or combinations thereof; and / or Molecules that have an affinity for T cell surface molecules and / or are able to bind to surface molecules present on T cells; Preferably, the immunoglobulin is selected from one or more combinations of IgG, IgA1, IgA2, IgD, IgE, and IgM; Preferably, the first and second domains are hinged together or linked by a peptide.

5. Biomaterials relating to the monoclonal antibody or its antigen-binding fragment as described in any one of claims 1-3 or the fusion antibody as described in claim 4, characterized in that, The biomaterial is any one of a1)-a12): a1) A nucleic acid molecule encoding the monoclonal antibody or its antigen-binding fragment as described in any one of claims 1-3 or the fusion antibody as described in claim 4; a2) An expression cassette containing the nucleic acid molecule described in a1); a3) A recombinant vector containing the nucleic acid molecules described in a1); a4) A recombinant vector containing the expression cassette described in a2); a5) Recombinant microorganisms containing the nucleic acid molecules described in a1); a6) Recombinant microorganisms containing the expression cassette described in a2); a7) Recombinant microorganisms containing the recombinant vector described in a3); a8) Recombinant microorganisms containing the recombinant vector described in a4); a9) Transgenic cell lines containing the nucleic acid molecules described in a1); a10) Transgenic cell lines containing the expression cassette described in a2); a11) Transgenic cell lines containing the recombinant vector described in a3); a12) Transgenic cell lines containing the recombinant vector described in a4).

6. A nanoparticle comprising lipid nanoparticles and an antibody modified on the surface of the lipid nanoparticles, wherein the antibody is a monoclonal antibody or an antigen-binding fragment thereof as described in any one of claims 1-3 or a fusion antibody as described in claim 4.

7. The nanoparticles according to claim 6, characterized in that, The lipid nanoparticles include phospholipids, structured lipids, and polymer-conjugated lipids; Preferably, the phospholipid is selected from at least one of dipalmitoylphosphatidylcholine, 1,2-dilinoleoyl-sn-glycerol-3-phosphate choline, 1,2-dimyristoyl-sn-glycerol-3-phosphate choline, 1,2-dioleoyl-sn-glycerol-3-phosphate choline, 1,2-dipalmitoyl-sn-glycerol-3-phosphate choline, 1,2-distearate-sn-glycerol-3-phosphate choline, and sphingomyelin; Preferably, the structural lipid is selected from at least one of cholesterol, coccosterol, sitosterol, ergosterol, campesterol, stigmasterol, campesterol, tomatine, ursolic acid and α-tocopherol; Preferably, the polymer-conjugated lipids include PEG-modified lipids; Preferably, the PEG-modified lipid is selected from at least one of PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic acid, PEG-modified ceramide, PEG-modified dialkylamine, PEG-modified diacylglycerol, and PEG-modified dialkylglycerol. Preferably, the mass ratio of the phospholipid, structural lipid and polymer-conjugated lipid is (3-6):1:(2-3).

8. The nanoparticles according to claim 7, characterized in that, The lipid nanoparticles also include cytotoxins; Preferably, the cytotoxic agent is selected from at least one of topoisomerase inhibitors, MMAE, MMAF, SN-38, gemcitabine, maytansine alkaloids, kazimidox, MGBA, doxorubicin, ricin, diphtheria toxin, or pyroxin SA.

9. The use of the monoclonal antibody or antigen-binding fragment thereof as described in any one of claims 1-3, the fusion antibody as described in claim 4, the biomaterial as described in claim 5, or the nanoparticle as described in any one of claims 6-8 in b1)-b4): b1) To prepare drugs or preparations for the prevention and / or treatment of tumors; b2) Prepare reagents or kits for detecting tumors; b3) Inhibit the expression of tubulin; b4) Prepare reagents, kits, or drugs to inhibit the expression of tubulin; Preferably, the tumors described in b1)-b2) include solid tumors or hematologic tumors.

10. A product comprising a monoclonal antibody or antigen-binding fragment thereof as described in any one of claims 1-3, a fusion antibody as described in claim 4, a biomaterial as described in claim 5, or nanoparticles as described in any one of claims 6-8.